Sales of drug delivery products are expected to increase by 100% over the next five years.
Sales of drug delivery products are expected to increase by 100% over the next five years as technologies currently being researched and developed reach fruition and are commercialized, according to "Drug Delivery Technologies and Markets," a new publication from London-based research company Informa Pharmaceuticals.
Currently, the market for special drug delivery technology is $50 billion a year, or 12.5% of world total pharmaceutical sales; by 2005, sales of delivery products are likely to exceed $100 billion, predicts the 200-page report. "Drug delivery will expand faster than the total pharmaceutical market," said Kewal Jain, author of the report.
Within this market, needle-free injector systems appear to be set for huge expansion from the current sales of $400 million a year, equivalent to 5% of the total needle/syringe market, to $1 billion by 2005. "Needleless injections could offer significant cost savings for cash-strapped health providers," said Jain. "The cost of needles and syringes is 1 million pound sterling per one million injections, whereas the same number of injections would cost 100,000 to 200,000 pounds using needleless injector systems."
Gene therapy is likely to be one of the most active growth sectors as biotech companies become involved in drug delivery. Currently, no product in this category has reached the market, but several are in phase III clinical trials. By the year 2005, some of these products will reach the market, with an estimated value of $5 billion. PR
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.